| scholarly article | Q13442814 |
| P50 | author | Chan Yoon Cheah | Q43162115 |
| Thorsten Zenz | Q46329248 | ||
| Susan O'Brien | Q66370727 | ||
| Loretta J Nastoupil | Q87358443 | ||
| Randy D Gascoyne | Q87831803 | ||
| Nathan H Fowler | Q88014314 | ||
| Sattva S Neelapu | Q91522188 | ||
| Catherine M Bollard | Q91774704 | ||
| Wyndham H. Wilson | Q110350523 | ||
| Kieron Dunleavy | Q114521842 | ||
| Paolo Ghia | Q38804038 | ||
| Michael A. Curran | Q39370315 | ||
| P2093 | author name string | Cliona Grant | |
| John Gribben | |||
| Stephen Ansell | |||
| Richard Little | |||
| P2860 | cites work | Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor | Q39984618 |
| Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy | Q40010311 | ||
| Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes | Q40037063 | ||
| Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. | Q40162985 | ||
| Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege | Q40272799 | ||
| Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. | Q40457809 | ||
| Distribution of the CD68 macrophage/myeloid associated antigen | Q41755919 | ||
| PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies | Q41826795 | ||
| Btk regulates macrophage polarization in response to lipopolysaccharide. | Q41882583 | ||
| Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting | Q42004205 | ||
| Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds | Q42106541 | ||
| B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. | Q42270144 | ||
| Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. | Q42351006 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors | Q43590484 | ||
| The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression | Q43621008 | ||
| The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation | Q44555005 | ||
| Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide | Q44599389 | ||
| Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma | Q44824307 | ||
| Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia | Q44930034 | ||
| Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells | Q45299110 | ||
| Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions | Q45885040 | ||
| High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. | Q46118408 | ||
| lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells | Q46482921 | ||
| Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). | Q46525283 | ||
| Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma | Q46702627 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor | Q28144319 | ||
| Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori | Q28249235 | ||
| Stromal gene signatures in large-B-cell lymphomas | Q28302107 | ||
| The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins | Q28303081 | ||
| Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells | Q28303091 | ||
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers | Q28306431 | ||
| Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor | Q28539394 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Natural innate and adaptive immunity to cancer | Q29620313 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy | Q30303054 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study | Q33373186 | ||
| Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma | Q33380246 | ||
| Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma | Q33383459 | ||
| Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma | Q33386521 | ||
| An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma | Q33393623 | ||
| Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial | Q33401684 | ||
| Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial | Q33406742 | ||
| Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study | Q33410282 | ||
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma | Q33413834 | ||
| Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. | Q51037023 | ||
| CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. | Q53095335 | ||
| Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. | Q53338355 | ||
| Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. | Q53611612 | ||
| Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-γ production by natural killer cells. | Q53820722 | ||
| Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. | Q54690954 | ||
| Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells | Q57279527 | ||
| IL-18 Induces PD-1-Dependent Immunosuppression in Cancer | Q57556330 | ||
| Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma | Q57631157 | ||
| IL-9 expression contributes to the cellular composition in Hodgkin lymphoma | Q62082808 | ||
| Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma | Q62597252 | ||
| Mantle cell lymphoma: a clinicopathological study of 55 cases | Q72148572 | ||
| Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a | Q73086806 | ||
| Mantle cell lymphoma: a clinicopathologic study of 80 cases | Q73128531 | ||
| Bone marrow and peripheral blood involvement in mantle cell lymphoma | Q74605653 | ||
| Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays | Q77351222 | ||
| Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients | Q79394017 | ||
| The kiss of death in FL | Q82568666 | ||
| Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma | Q84847984 | ||
| Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype | Q85804046 | ||
| High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages | Q87513562 | ||
| Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial | Q33418964 | ||
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma | Q33690142 | ||
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma | Q33962334 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Oncology meets immunology: the cancer-immunity cycle | Q34037625 | ||
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor | Q34041792 | ||
| Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma | Q34042407 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired | Q34080914 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| Pathogenesis of human B cell lymphomas | Q34245261 | ||
| Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial | Q34391446 | ||
| Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. | Q34402339 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | Q34568868 | ||
| IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells | Q34636880 | ||
| Regulation of B-cell fate by antigen-receptor signals | Q35014068 | ||
| Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). | Q35064910 | ||
| Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia | Q35146081 | ||
| Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK | Q35156866 | ||
| Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma | Q35220644 | ||
| Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia | Q35671227 | ||
| CD40 activation: potential for specific immunotherapy in B-CLL. | Q35777555 | ||
| Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma | Q35794450 | ||
| Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma | Q35849633 | ||
| Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning | Q35986612 | ||
| Mechanisms of B-cell lymphoma pathogenesis | Q36085626 | ||
| Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer | Q36177909 | ||
| Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. | Q36253967 | ||
| Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial | Q36333526 | ||
| Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation | Q36362226 | ||
| Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells | Q36370860 | ||
| High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. | Q36628291 | ||
| T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. | Q36654128 | ||
| Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. | Q36715966 | ||
| Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial | Q36715971 | ||
| The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. | Q36892616 | ||
| Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial | Q36929714 | ||
| Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. | Q37004749 | ||
| Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells | Q37144907 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma | Q37333645 | ||
| Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor | Q37354362 | ||
| Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy | Q37427993 | ||
| Environment-mediated drug resistance: a major contributor to minimal residual disease | Q37582773 | ||
| Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome | Q37659012 | ||
| Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. | Q37867290 | ||
| The microenvironment in follicular lymphoma | Q37887136 | ||
| The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies | Q37938355 | ||
| Bruton tyrosine kinase (BTK) and its role in B-cell malignancy | Q37997075 | ||
| Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies | Q38076576 | ||
| The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. | Q38122535 | ||
| The targeting of immunosuppressive mechanisms in hematological malignancies | Q38201231 | ||
| The tumour microenvironment in B cell lymphomas | Q38227748 | ||
| Recurrent genomic rearrangements in primary testicular lymphoma. | Q38387704 | ||
| Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma | Q38389777 | ||
| CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. | Q38992830 | ||
| Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia | Q39105456 | ||
| Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma | Q39433857 | ||
| Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells | Q39548715 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance | Q39798268 | ||
| Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo | Q39831203 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 531-40 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Role of the tumor microenvironment in mature B-cell lymphoid malignancies | |
| P478 | volume | 101 |
| Q90331515 | Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation |
| Q58582706 | Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma |
| Q88801099 | Follicular Lymphoma: Past, Present, and Future |
| Q39027770 | Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy? |
| Q48156058 | Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells |
| Q51770984 | IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. |
| Q49961097 | Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. |
| Q94545651 | Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program |
| Q93087115 | M1-like macrophage polarization prevails in young children with classic Hodgkin Lymphoma from Argentina |
| Q57174502 | Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective |
| Q38683034 | Mechanisms of Immune Tolerance in Leukemia and Lymphoma |
| Q47567402 | Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. |
| Q39423479 | Regulatory myeloid cells: an underexplored continent in B-cell lymphomas |
| Q49226138 | The evolving role of targeted biological agents in the management of indolent B-cell lymphomas. |
| Q92847525 | The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma |
| Q45938784 | Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells. |
| Q64949581 | Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. |
| Q99710992 | Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma |
| Q30238528 | When to treat patients with relapsed follicular lymphoma |
| Q33815997 | c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells |
Search more.